Good morning - Pasted below is the report from the first PSMA PET scan my husband has had that has shown possible mets or anything other than activity in the prostate since he started Intermittent ADT about two years ago.
I am hoping for some guidance on what to expect/what to ask for in terms of further testing and/or possible treatment options based on this scan? Also, is it possible that what they are seeing in C-spine and pelvis could be something other than metastases? If they are suspected mets, what testing would confirm that? And if confirmed, what treatment options might he consider? Is the only option other ADT treatment or is there something that can target the mets?
My bio should be current but to summarize, he was metastatic at diagnosis In January 2022. He had successful treatment with Triple Therapy. By late February 2023, it was primarily significant mental health side effects that led to his request to begin intermittent treatment. After his first PSA rise during his first break, his MO offered different treatments (Orgovyx, and I believe Casodex) and he opted for Enzalutamide/Xtandi. Due to his having had a grand mal seizure back in 2017, his MO put him on a half dose (two tablets rather than four). Since then, it has done the job of lowering his PSA significantly. Each time he has been given a break it has been coupled with scans showing no new activity as mentioned above, and other labs looking good.
Also, I should note that other than what I mentioned above, my husband has had no other treatment (no radiation, etc.). And, he has not had any genetic testing since early 2022, when they tested blood and tissue from a lymph node biopsy. At the time, there were no actionable mutations. His new MO has said that if anything shows that can be biopsied, she will want to do that to see if anything has changed in that regard.
I appreciate any guidance. We meet with the MO tomorrow morning.
Thanks in advance.
EXAM: GALLIUM-68 PSMA PET/CT CLINICAL HISTORY: Patient with prostate cancer. Gleason 4+4 [8] prostate cancer metastatic to bone and lymph nodes. PSA on February 01, 2025 was 11.13 ng/ml.
TECHNIQUE: Radiopharmaceutical: 6.5 mCi Ga-68 PSMA intravenously Uptake time: Body:62Pelvis:96Field of view: Vertex of skull to upper thigh Oral Contrast: Not administered IV Contrast: Not administered The CT protocol used for this PET/CT study is designed for attenuation correction and anatomic localization of PET abnormalities. This companion CT is not designed to produce, and cannot replace, state-of-the-art diagnostic CT scans with specific imaging protocols for different body parts and indications. The standardized uptake values (SUV) are normalized to patient body weight and indicate the highest activity concentration (SUVmax) in a given disease site.
COMPARISON: September 20, 2024. CORRELATION: None.
FINDINGS: REFERENCE REGIONS: Parotid gland SUV mean: 15.Liver SUV mean: 5.8.Blood pool at aortic arch SUV mean: 1.5.
HEAD/NECK: No abnormal uptake.
CHEST/BREAST: No abnormal uptake. Bilateral gynecomastia. LUNGS: No abnormal uptake. Calcified granuloma right lung unchanged.
PLEURA/PERICARDIUM: No abnormal uptake.
MEDIASTINUM/THORACIC NODES: No abnormal uptake. Minimally avid nonenlarged right axillary node, SUV 1.9, image 104, probably reactive. Low-grade right perihilar uptake, possibly nodal, SUV 2.3, image 117, previously SUV 2.4.
HEPATOBILIARY: No abnormal uptake.
SPLEEN: No abnormal uptake.
PANCREAS: No abnormal uptake.
ADRENAL GLANDS: No abnormal uptake.
KIDNEYS/URETERS/BLADDER: No abnormal uptake.
ABDOMINOPELVIC NODES: No abnormal uptake.
GI/PERITONEUM/MESENTERY: No abnormal uptake.
PELVIC ORGANS: Discrete tracer uptake at the left prostate base inseparable from the seminal vesicle SUV 7.6, image 252, previously SUV 8.0Focal uptake at the right lateral base to mid prostate SUV 9.3, image 264, previously SUV 7.4. Trace bilateral hydrocele. Left greater than right fat-containing inguinal hernias.
BONES/SOFT TISSUES: Increased intensity of focal uptake at the left lateral C2 vertebral body SUV 10.8, previously SUV 3.5.Low-grade uptake at the C3 vertebral body SUV 3.6, new.No substantial change in rim sclerotic bilateral iliac bone lesions with below background uptake, SUV 1.0 on the left, image 227 and SUV 1.1 on the right, image 227Faintly sclerotic focus at the right inferior pubic ramus, image 269, SUV 1.2, image 269, new.
OTHER FINDINGS: None.
IMPRESSION:
1. Since PET/CT September 20, 2024, no substantial change in tracer uptake at the left prostate base and slightly increased intensity of tracer uptake at the right lateral base to mid prostate gland. Suspicious for viable tumor.
2. Increased intensity of tracer uptake at the C2 vertebral body and new low-grade uptake at the C3 vertebral and right inferior pubic ramus, suspicious for metastatic disease.
3. Unchanged few mixed lucent/sclerotic osseous lesions.